Highlights d Characterization of the mutational landscape of secondary glioblastoma d Clonal and subclonal METex14 promote glioma progression and mark worse prognosis d PLB-1001 is a highly selective, efficient, and BBB-permeable MET kinase inhibitor d PLB-1001 provides a safe and efficacious therapeutic approach for glioma treatment SUMMARY Low-grade gliomas almost invariably progress into secondary glioblastoma (sGBM) with limited therapeutic option and poorly understood mechanism. By studying the mutational landscape of 188 sGBMs, we find significant enrichment of TP53 mutations, somatic hypermutation, MET-exon-14-skipping (METex14), PTPRZ1-MET (ZM) fusions, and MET amplification. Strikingly, METex14 frequently co-occurs with ZM fusion and is present in $14% of cases with significantly worse prognosis. Subsequent studies show that METex14 promotes glioma progression by prolonging MET activity. Furthermore, we describe a MET kinase inhibitor, PLB-1001, that demonstrates remarkable potency in selectively inhibiting MET-altered tumor cells in preclinical models. Importantly, this compound also shows blood-brain barrier permeability and is subsequently applied in a phase I clinical trial that enrolls MET-altered chemo-resistant glioma patients. Encouragingly, PLB-1001 achieves partial response in at least two advanced sGBM patients with rarely significant side effects, underscoring the clinical potential for precisely treating gliomas using this therapy.
In Brief
A new MET inhibitor shows preliminary efficacy for treatment of patients with secondary glioblastoma.
INTRODUCTION
According to the World Health Organization (WHO) classification of tumors of the CNS, malignant adult diffused gliomas are classified into grades II to IV based on histologic features (Louis et al., 2016) . Grade IV gliomas, or glioblastoma (GBM), can be further classified into primary GBM (pGBM) and secondary GBM (sGBM) (Wen and Kesari, 2008) . Mostly IDH wild-type, pGBM is de novo developed and commonly found in the elderly. In contrast, sGBM typically affects younger patients and progresses from low-grade diffuse astrocytoma or oligodendroglioma within 5-10 years of diagnosis (Louis et al., 2016) . The limitations in current chemotherapy using temozolomide (TMZ), which functions by nonselective DNA damage, includes side effects and chemo-resistance. Under this therapy, almost all patients will recur, and the recurrent tumors usually carry distinct alterations that might lead to drug-resistance . To improve glioma treatment, it is essential to identify new oncogenic alterations and design therapies to specifically target them.
Although the mutational (Brennan et al., 2013; Ceccarelli et al., 2016; Brat et al., 2015) and evolutionary landscapes Wang et al., 2016) of GBM have been well studied, the genomic and transcriptomic features and evolution mechanisms of the progression from LGG to sGBM remain elusive. Recent longitudinal studies that collected paired LGG and sGBM samples illustrated the roles of PI3K/Akt/mTOR pathway, RB pathway (Bai et al., 2016; Johnson et al., 2014) , cell-cycle regulations (Mazor et al., 2015) , and DNA methylation reprogramming (Mazor et al., 2017) during glioma progression. However, all of these studies enrolled <20 sGBM patients, which limits the statistical power. To date, actionable solutions have rarely been provided. Thus, a large-scale retrospective and prospective investigation is required to reveal the mutational landscape of sGBM and to seek approaches of translating these findings into clinical practice.
Here, we describe an integrated genomic and transcriptomic analysis of 188 sGBM patients and reveal the comprehensive mutational landscape of sGBM. Comparing the profile of sGBM with that of LGG and pGBM, we found that MET alterations, including MET exon 14 skipping (METex14) and PTPRZ1-MET (ZM) fusion, are highly enriched in sGBM. Functional studies of MET alterations in cell lines and xenografts demonstrated hyper-activation of MET signaling pathway and acceleration of tumor proliferation. In addition, we investigated the microenvironment and showed the enrichment of tumor-associated macrophages in patients with both METex14 and ZM fusion. A MET-specific inhibitor, PLB-1001, was then characterized and demonstrated effective suppression of MET-induced glioma progression in cell lines and xenografts. Finally, in an open-label phase I clinical trial, we demonstrated the safety and efficacy of PLB-1001 in patient treatment. Taken together, we described a comprehensive somatic mutation landscape of sGBM and provided a MET-targeted therapy for precision neuro-oncology.
RESULTS

Mutational Landscape of sGBM
To reveal the mutational landscape of sGBM, we collected and integrated genomic and/or transcriptomic data from 188 sGBM patients (Table S1 ), including 104 newly collected samples from the Chinese Glioma Genome Atlas (CGGA), 4 newly collected samples from the Samsung Medical Center (SMC), and previously published resources (Bao et al., 2014; Brennan et al., 2013; Johnson et al., 2014; Kim et al., 2015a Kim et al., , 2015b McLendon et al., 2008; Parsons et al., 2008; Suzuki et al., 2015; Wang et al., 2016) ( Figure S1A ; Table S1 ; STAR Methods). The landscape of somatic mutations of 145 patients with DNA sequencing (i.e., whole genome, whole exome, or targeted sequencing) revealed mutations and/or deletions in TP53, ATRX, CIC, FUBP1, CDKN2A, RB1, and PTEN-PI3K pathway and mutations and/or amplifications in MET, EGFR, PDGFRA, and CDK4 ( Figure 1A) . In 78 patients with RNA sequencing data, METex14 was detected in 14% (95% confidence interval [CI] , 8.0%-23.5%) of sGBM cases (Figures S1B and S1C). Sanger sequencing validated this event in patients with available samples ( Figure S1D ). Additionally, various ZM fusions were identified in four sGBM cases (5% with 95% CI, 2.6%-7.6%), all of which simultaneously harbor METex14 ( Figure 1A) . Missense mutations on Arg132 of IDH1 were observed in 67% of sGBMs, similar as reported previously (Nobusawa et al., 2009; Ohgaki and Kleihues, 2013) . The IDH1 mutation status showed no association with METex14 alteration (p > 0.5, Fisher's exact test). Not surprisingly, we found mutations in TP53, ATRX, CIC, and FUBP1 were more frequent in IDH1 mutant cases, while PTEN and EGFR mutations were enriched in IDH1 wild-type cases (p < 0.05 by Fisher's exact test, Figure S1E ). In addition, by integrating data across platforms (STAR Methods), we identified 18 hypermutated cases out of 142 sGBM patients in Asian populations and 13 out of 39 in Caucasian population ( Figure S1F ). Hypermutation was found to be higher in Caucasian population and closely associated with TMZ treatment (Table S1 ).
Divergence of sGBM from Low-Grade Glioma and Primary GBM
To systematically compare LGG, pGBM, and sGBM, we characterized genomic alterations of the sGBM cohort and acquired genomic data of pGBM and LGG from The Cancer Genome Atlas (TCGA) (Brennan et al., 2013; Ceccarelli et al., 2016) . We observed in pGBM a higher frequency of alterations in EGFR, PTEN, PDGFRA, CDK4, CDKN2A, PIK3CA, and RB1 (Brennan et al., 2013) (left corner at Figure 1B ; Table S2 ). As expected, alterations in CIC, FUBP1, TP53, ATRX, and IDH1 were more common in LGG and sGBM. Particularly, IDH1 mutations were observed in 77% of LGG, 67% of sGBM, but only 5% of pGBM. Hypermutation was found in 16% of sGBM, which was comparable with recurrent GBM (17%) . Additionally, higher frequencies of alterations in MTOR, NF1, RB1 (Bai et al., 2016; Johnson et al., 2014) , and MET were observed in sGBMs over LGG (Table S2 ), suggesting that they were potentially related to the progression of LGG. Interestingly, METex14, ZM, and MET amplification were significantly enriched in sGBM (p = 4.0 3 10 À7 , 1.2 3 10 À2 , and 2.0 3 10 À4 by Fisher's exact test, Figure 1B) . Remarkably, the frequency of METex14 in sGBM (11/78) was significantly higher than those in LGG (6/530, p = 5.3 3 10 À7 ) and pGBM (3/174, p = 2.3 3 10 À4 , Fisher's exact test, Figure 1C ). By defining sGBM overall survival (OS) as the period from the first diagnosis of sGBM until patient death ( Figure 1D ), we observed that sGBM patients with METex14 showed significantly poorer OS compared to those without METex14 ( Figure 1E ), suggesting that METex14 was a prognostic marker for glioma patients.
METex14 Promotes MET Signaling Hyper-activation and Glioma Progression
Various genomic mutations were observed in patients with exon 14 skipping on MET transcript (deletion of entire exon 14 in Figure 2A , disruption of its splice donor site in Figure S2A ). MET exon 14 encodes the juxta-membrane (JM) domain on MET, which contains the phosphorylation site Tyr1003 (Y1003) required for c-Cbl-mediated ubiquitination and degradation of MET. Therefore, METex14 results in prolonged stability and constitutive activation of MET (Frampton et al., 2015) ( Figure 2B ). In METex14-positive samples, we observed elevated expression of MET transcript ( Figure S2B ). The degradation signal marked by JM domain Y1003 phosphorylation, however, was abolished by METex14 ( Figure 2C ), which leads to reduced MET degradation. As STAT3 acts downstream of MET signaling and plays essential roles in MET-mediated tumorigenesis (Zhang et al., 2002) , we examined the effects of MET alterations on STAT3 activation. Immunohistochemistry (IHC) and histology staining of paired LGG and progressed sGBM samples (P068) with both ZM fusion and METex14 demonstrated hyper-activation of MET/STAT3 signaling pathway and elevated proliferation and angiogenesis activities while progressing into the METex14-positive sGBM ( Figure 2D ). Moreover, METex14 expression is dramatically elevated during LGG progression in 3 out of 4 patients who have longitudinal sequencing samples ( Figure 2E ). Thus, we hypothesize that subclones harboring these mutations are positively selected and fast proliferating during tumor progression. In agreement with our hypothesis, sGBMs with METex14 at clonal and subclonal level both showed significantly poorer OS compared to METex14-negative patients ( Figure S2C ), indicating that the clonal expansion of METex14 might contribute to shortened patient survival.
Characterization of Different MET Alterations
By integrating all 782 glioma patients (combined cohort of sGBM, pGBM, and LGG), we discovered a strong tendency of METex14 and ZM fusion to co-occur (p < 1.0 3 10 À4 by Fisher's exact test, Figure 3A ). Cloning the full-length ZM fusion transcript from the cDNA library of sGBM, we found intact MET exon 14 on the same transcript, suggesting that MET fusion and METex14 probably occur on different copies of MET in 54%   P024  P040  P138  P027  P114  P208  P113  P193  P215  P220  P038  P054  P222  P143  P068  P069  P207  P096  P099  P216  P221  P142  P191  P097  P196  P127  P078  P129  P131  P134  P135  P146  P192  P041  P186  P118  P050  P115  P123  P089  P125  P077  P128  P187  P037  P144  P066  P055  P073  P116  P132  P062  P034  P030  P029  P204  P023  P043  P133  P200  P052  P101  P137  P217  P028  P026  P130  P025  P092  P098  P121  P136  P036  P056  P057  P124  P067  P072  P104  P112  P126  P110  P044  P100  P063  P206  P064  P079  P205  P218  P210  P109  P087  P031  P053  P032  P065  P085  P061  P140  P091  P088  P074  P194  P075  P190  P198  P070  P201  P195  P058  P035  P049  P046  P060  P071  P080  P105  P119  P059  P199  P045  P120  P107  P117  P145  P033  P211  P017  P094  P095  P202  P076  P093  P108  P122  P203  P209  P082  P081  P083  P048  P111  P047 Figure S1 and Tables S1 and S2. the genome, resulting in the production of MET protein with either PTPRZ1 chimera sequence at its N-terminal or with skipped JM domain ( Figure S3A ; Data S1). (legend continued on next page) respectively. As a result, 1,453 genes were found to be differentially expressed in METex14-or ZM-positive sGBM, with more genes upregulated than downregulated in both groups. MET, H19, CACNG5, and genes in DNA repair pathway showed elevated expression in both METex14-and ZM-positive samples, while FGFR3 and CDKN2A were downregulated. The fold change of the differentially expressed genes in METex14-positive and in ZM-positive samples were highly correlated (Pearson's correlation coefficient = 0.90), indicating similar effects of METex14 and ZM on gene expression ( Figure 3B ).
We further assessed the oncogenic effects of MET alterations on glioma cells by generating human astrocyte (HA) and patientderived IDH wild-type GBM (N33) cell lines that overexpress MET or ZM fusions using adenovirus transduction. Expression of both MET and ZM fusions resulted in hyper-activation of MET and STAT3 signaling ( Figure 3C ). Furthermore, the U87 MG cells with lentivirus-mediated ZM expression had a higher cell proliferation rate ( Figure S3B ). On the xenograft model generated by subcutaneous implantation in BALB/c nude mice, tumors of U87 MG cells overexpressing the ZM fusion grew more rapidly than did tumors formed by cells transduced with control vector ( Figure S3C , p = 2.0 3 10 À3 ). The same U87 MG cells stably expressing the ZM fusion were also injected into the brains of BALB/c nude mice. Tumors derived from ZMharboring U87 MG cells grew more rapidly as shown by magnetic resonance imaging (MRI) examination at 30 days after transplantation ( Figure S3D ), resulting in significantly poorer OS (p = 4.0 3 10 À4 , Figure S3E ). Immunostaining showed higher level of activation of MET and STAT3 signaling in intracranial tumors harboring ZM fusion than in tumors without ZM fusion ( Figure 3D ).
Tumor-associated macrophages are known to be highly abundant in high-grade glioma, where they promote tumor proliferation, invasion, angiogenesis, and suppress immune responses (Hambardzumyan et al., 2016) . Comparing sGBM with LGG and pGBM samples, we observed more enriched tumor-associated macrophages in sGBM compared to LGG, but less enriched in sGBM compared to pGBM ( Figure S3F ). Moreover, in sGBM patients, elevated number of macrophages was also identified in METex14-positive sGBM that co-occurred with ZM fusions ( Figures 3E and S3G ). We validated this observation by IHC staining of a macrophage marker, IBA1, on two sGBM samples with METex14 and ZM fusion as well as two control samples without any MET alterations ( Figure 3F ). Quantifying the percentage of IBA1 staining-positive cells in randomly selected scan fields from each sample, significantly higher fraction of macrophages were observed in sGBM with concurrent METex14 and ZM fusion ( Figure 3G ), suggesting that MET alterations may contribute to tumor malignancy by recruiting tumor-associated macrophages and altering the glioma microenvironment. Thus, our analysis suggests the diverse roles of MET alterations in glioma progression by activating MET signaling, promoting tumor growth, and altering the tumor microenvironment.
PLB-1001 Is a Highly Selective MET Inhibitor with Blood-Brain Barrier Permeability Several MET inhibitors have been developed, yet insufficient induction of tumor regression and rapid development of acquired resistance remain unresolved challenges in MET inhibitor-mediated cancer therapies (Bender et al., 2016; Gherardi et al., 2012; Lai et al., 2014) . Four MET inhibitors, crizotinib (a dual-targeted inhibitor of MET and ALK kinases) (Cui et al., 2011) , cabozantinib, foretinib, and INCB28060, and 56 non-MET inhibitors were applied to a ZM-positive and a METex14-positive patientderived glioma cell line, respectively, to test the sensitivity of the cell lines to the drugs (STAR Methods). MET inhibitors demonstrated significantly better growth inhibition effects than non-MET-inhibitors on the both cell lines (Wilcoxon rank-sum test, p = 4.0 3 10 À3 , Figure S3H ; and p = 9.0 3 10 À4 , Figure S3I ), suggesting good potential of MET inhibitors to treat gliomas with MET alterations.
We described a highly selective ATP-competitive smallmolecule MET inhibitor, PLB-1001 ( Figure 4A ; STAR Methods). To elucidate the molecular structure of PLB-1001 in complex with its target, we performed molecular dynamics simulation using the tyrosine kinase domain structure of MET as the starting model ( Figure 4A ). PLB-1001 binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily. Similar to the structure of the complex formed by crizotinib with the same domain (Cui et al., 2011) , PLB-1001 occupied the bulk of the ATP-binding pocket. However, the cyclopropyl moiety of PLB-1001 was trapped into the hydrophobic groove that was formed by the side chains of Ile1084, Tyr1159, Met1211, and Asp1164. Moreover, the indazol moiety of PLB-1001 bound to another cleft, which was formed by the side chains of Asp1204, Arg1208, Pro1246, and the main chain atoms of Gly1224 and Asp1228. In contrast, these two binding pockets were not involved in the stabilization of crizotinib. Of note, the piperidine moiety of crizotinib clearly pointed toward the solvent and did not interact with the kinase molecule. The additional interactions of PLB-1001 with the kinase indicated a higher binding affinity and a better inhibition effect compared with crizotinib. To test the selectivity of PLB-1001, LANCE enzyme assays were performed to test the efficiency of PLB-1001 in inhibiting 100 kinases through detection of the level of ULight/CREBtide-substrate phosphorylation after incubation with 2 mM of PLB-1001 (Table S3 ; STAR Methods). The kinase inhibition assay showed that PLB-1001 inhibited MET activity (E) Tumor-associated macrophages in patients harboring the METex14 and ZM fusion (n = 4) compared to patients with wild-type MET (n = 74) by CIBERSORT (p = 2.5 3 10 À2 by Wilcoxon rank-sum test). The box shows the quartiles of the dataset while the whiskers extend to show the rest of the distribution. (F) Immunohistochemistry staining of two ZM-negative samples and two METex14-positive sGBM with ZM fusion (P068 and P053) with antibody against macrophage marker Iba1. Scale bars, 20 mm. (G) Percentage of Iba1 + cells per scan field was quantified from immunohistochemistry staining. Fifty scan fields were randomly selected from each patient (5 whole-slide imaging per patient, 10 randomly selected scan fields per image). p value of sGBM samples harboring MET alterations was calculated by Wilcoxon rank-sum test against two MET wild-type samples. The box shows the quartiles of the dataset while the whiskers extend to show the rest of the distribution. See also Figure S3 and Data S1. by 95.1%, whereas other kinases, including kinases in the same family as MET (Manning et al., 2002) , were barely inhibited, confirming the high selectivity of PLB-1001 for MET kinase ( Figure 4B ; list of assayed kinases in Table S3 ). To test the efficacy of PLB-1001 in targeting MET alterations, human astrocytes expressing exogenous ZM fusion or METex14 were used. Similar with crizotinib, PLB-1001 inhibited the phosphorylation of MET and STAT3, indicating a robust inhibitory effect of PLB-1001 on MET and its downstream signaling pathways ( Figure 4C ).
We then employed the MDCK (Madin-Darby canine kidney)-MDR1 cell line (Cecchelli et al., 2007) to compare the permeability and efflux rate of PLB-1001, temozolomide, and three other MET-targeted drugs (crizotinib, cabozantinib, and foretinib). The apparent permeability and efflux rate of each drug was calculated from the liquid chromatography-tandem mass (E) PLB-1001 concentration in rat brain following intragastric administration of 4.5 mg/kg body weight of PLB-1001 (n = 6). Data are presented as means ± SD. See also Figure S3 and Tables S3 and S4. spectrometry (LC-MS/MS)-detected drug concentration across the MDCK-MDR1 cell monolayer (see STAR Methods). PLB-1001 has higher apparent permeability and lower efflux rate than other MET inhibitors (crizotinib, cabozantinib, and foretinib) in MDCK-MDR1 cell model ( Figure 4D ). The two essential bloodbrain barrier (BBB) transporters, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), do not bind and efflux PLB-1001, as the efflux rate of PLB-1001 across monolayers of the P-gp-expressing MDCK-MDR1 or the BCRP-expressing Caco-2 is similar with that of non-substrates (Figures S3J and S3K) with no significant changes in response to BCRP inhibitor treatment ( Figure S3L ). We then tested the PLB-1001 concentration in the brain of Sprague-Dawley rats and found a peak of 0.207 mg/g (with brain/total plasma ratio $1.75%) of tissue weight at 3 hr after intragastric administration of 4.5 mg/kg body weight of PLB-1001 (corresponds to 50 mg bis in die [bid] dose in human [body weight of 70 kg]), and the concentration then declined gradually ( Figure 4E ; Table S4 ). In summary, PLB-1001 shows superior specificity in MET inhibition and is permeable in crossing the BBB in cell and rat models.
PLB-1001 Suppresses Tumor Progression Driven by MET Alterations
In the ZM-harboring U87 MG xenograft models, PLB-1001 and crizotinib were administered when the subcutaneous tumors reached a volume of $100 mm 3 . PLB-1001 treatment resulted in a significant reduction in the growth of ZM-harboring xenografts compared with crizotinib and vehicle ( Figures 5A-5C ). Furthermore, PLB-1001 and crizotinib inhibited MET phosphorylation, and increased Cdk2 pTyr15 phosphorylation ( Figure 5D ), indicating inhibition of MET signaling and tumor growth in the xenograft model.
Treatment of mice carrying intracranial orthotopic tumors derived from the same ZM-expressing glioma cell line with PLB-1001 from 14 days post-implantation showed suppressed tumor growth until 30 days post-implantation by MRI examination, which subsequently reverted to active growth following the withdrawal of PLB-1001 ( Figure 5E ). PLB-1001 treated mice showed a longer OS compared to untreated controls (Figure 5F) . HE and IHC staining of the orthotopic tumors showed diminished staining intensities of p-MET, p-STAT3, Ki-67, CD31, and pHH3 following PLB-1001 treatment ( Figure 5G ).
Together, these findings demonstrate that PLB-1001 treatment inhibited MET signaling, proliferation, and angiogenesis activities in the xenograft models with MET alterations.
Safety and Efficacy of PLB-1001 in Glioma Patients with MET Alterations
To further explore the safety and efficacy of PLB-1001 in patients, we translated these findings into the clinic. We have conducted a phase I, open-label study of PLB-1001 administered orally to recurrent high-grade gliomas patients with ZM fusion and/or METex14 ( Figure 6A ; STAR Methods). The aim of the 3+3 dose-escalation study is to estimate the maximum tolerated dose (MTD) and to identify the dose-limiting toxicity (DLT) and the recommended phase II dose (RP2D) for PLB-1001 single agent as well as to determine the pharmacokinetic/pharmacodynamics (PK/PD) profile. In total, 18 recurrent high-grade glioma patients (P01001-P01018), including 9 sGBMs and 9 grade III gliomas, carrying ZM fusions and/or METex14 were enrolled. These 18 patients, ranging from 31 to 66 years of age, were initially diagnosed with lower-grade glioma. At recurrence, the histopathological and molecular study after resection showed that their tumors have progressed into high-grade glioma with MET alterations. Routine TMZ treatment has been delivered either after recurrence or at initial diagnosis. They were enrolled into the PLB-1001 clinical trial at later tumor progression or recurrence events. In the trial, patients were treated by PLB-1001 with dosage ranging from 50 to 300 mg bid (Table S5 ). After single-dose treatment, PLB-1001 reached stable plasma concentration between 1,000 to 6,000 ng/mL in 24 hr ( Figure 6B ). The PLB-1001 concentration in the cerebrospinal fluid (CSF) collected on day 15 was $3%-8% of that in plasma and showed an increasing trend with the drug dosage ( Figure 6C ). More detailed clinical characters were summarized in Table S5 and  Figures 7A , S4, S5, and S6A-S6C.
The drug safety and potential adverse events (AEs) were carefully investigated (Table S5 ). Up to the study cutoff date, three sGBM patients withdrew from the trial because of trial-unrelated clinical events, including dysphagia, drug-unrelated tumor stroke, and pneumonia, and no DLT effects or deaths occurred. No MTD had been reached. Grade 3 AEs of hepatotoxicity were observed in two patients with grade III glioma, including increased ALT in one patient treated with 200 mg bid dosage at week 12 and increased total bilirubin in another patient treated with 300 mg bid dosage at week 7 ( Figure 6D ). These grade 3 AEs did not occur within the DLT observation period (4 weeks from the start of PLB-1001 treatment) and hence they were not considered as DLT. Common grade 1-2 AEs including increased serum lipase and glutamic oxalacetic transaminase and decreased albumin were observed. To evaluate the treatment outcome, the Response Assessment in Neuro-Oncology (RANO) criteria (Wen et al., 2017) has been used. Overall, out of the six sGBM patients who stayed in the trial, two achieved partial response (PR), two achieved stable disease (SD), and two had progressed disease (PD) ( Figures 6D and 6E ). Among the nine grade III glioma patients, five achieved SD and four had PD ( Figures 6D and 6E ; Table S5 ).
To determine the RP2D, pharmacokinetic test was performed and demonstrated that the plasma concentration in patients treated with 300 mg dosage had reached the corresponding 90% effective dose (ED90) in ZM-positive U87 cell line-derived xenograft models ( Figure S6D ; Table S6 ; STAR Methods). Taking into consideration the potential long-term toxicity effects, we recommend PLB-1001 monotherapy dosage as 300 mg bid.
The disease progression of the two sGBM patients who achieved PR was closely monitored by MRI scanning. Under PLB-1001 treatment, tumor shrinkage accompanied with symptom relief was observed in patients P01001 ( Figure 7B ) and P01011 ( Figure S6E ), and no radiological progression was detected in 16 weeks. However, at the 20 th week of treatment, both patients showed non-measurable progression under RANO criteria (Wen et al., 2010) , but symptom relief of the two patients continued. For P01001, the recurrent tumor was developed at the same location prior to the treatment and was resected and profiled by whole-genome and transcriptome sequencing. We then constructed the phylogenetic tree of this patient and found gained mutations in PIK3CA, PIK3CG, PTEN, MSH2, and deletions in RB1 and CIC at recurrence after PLB-1001 treatment (Figure 7C ). Single-sample gene set enrichment analysis (ssGSEA) analysis revealed elevated activity of PI3K-Akt-mTOR pathway in the recurrent tumor ( Figure 7D ), suggesting a potential mechanism of MET inhibitor resistance, which is in accordance with the observation that cell lines with both METex14 and PIK3CA mutation do not respond to MET inhibitor monotherapy . In this phase I clinical trial, PLB-1001 monotherapy demonstrated a safety profile for sGBM or grade III glioma patients with ZM fusion and/or METex14. The median duration of response and PFS are 62.5 days and 80 days, respectively, and 7 out of 15 patients achieved PFS3. Recommended PLB-1001 monotherapy dosage is 300 mg bid.
DISCUSSION
By far, our study collected the largest cohort of sGBMs, combining cases from the AGGA and published datasets. The newly collected samples from East Asian population may reflect the difference between ethnic groups, which is an important factor in the implementation of precision medicine. We observed significantly higher rate of hypermutation in Caucasian than in Asian population, which may be contributed to by genetic background, environment factors, or the applied dose of TMZ.
In addition to previous reports of ZM fusion in glioma (Bao et al., 2014; Frampton et al., 2015) , our study further identified Figure 7 . Case Study of a Patient Who Achieved Partial Response (A) Diagram of the glioma progression and treatment in patient P01001. The patient was initially diagnosed of low-grade astrocytoma, which was resected and treated with radiotherapy. The tumor recurred locally and progressed into high-grade sGBM after 2 years and was surgically removed and treated by 6 cycles of temozolomide. As METex14 and ZM fusion was detected in this sGBM sample, the recurrent sGBM in the patient was later subscribed with 5 cycles of PLB-1001 treatment. At week 20 of treatment, the tumor recurred at the margin of resection area, and this recurrent sGBM was surgically removed and sequenced. (B) The tumor (P01001) was monitored by MRI evaluation every 4 weeks (tumor site is marked by arrows). Tumor shrinkage was observed after 4 weeks of PLB-1001 treatment, and no radiological progression was detected until week 20 of treatment. (C) The tumor evolution tree of P01001 was inferred from the whole genome and whole transcriptome sequencing of tumor samples from sGBM and the recurrent sGBM (rsGBM) after PLB-1001 treatment. Whole genome sequencing of the blood sample was used as normal control. (D) Applying the single-sample gene set enrichment analysis (ssGSEA) on significantly upregulated genes in rsGBM versus sGBM. Elevated PI3K-Akt-mTOR pathway is detected at recurrence (NES = 1.554, q value = 1.1 3 10 À2 ). the enrichment of METex14 in sGBM and elucidated their roles in driving glioma progression. METex14 was also highly recurrent in lung cancer, and accelerated cell proliferation in vitro and in xenograft of small cell lung cancer cell lines (Kong-Beltran et al., 2006) . Co-occurring of METex14 and ZM fusion is associated with enriched tumor-associated macrophages (TAM), which was reported to be associated with poor prognosis in glioma (Hambardzumyan et al., 2016; Shi et al., 2017) . Co-occurrence of TPR-MET fusion and METex14 was reported to generate a chimeric protein with TPR dimerization domain and MET kinase domain, while excluding the JM domain (Cooper et al., 1984) . Inclusion of exon 14 reduced the oncogenic potential of this fusion gene (Vigna et al., 1999) , suggesting the role of MET exon 14 in regulating MET degradation. However, in the case of ZM fusion, the full-length transcript of ZM from patients show inclusion of the exon 14, suggesting mutations resulting in METex14 and ZM fusion occur on different copies of MET genes. Due to the scarcity of cases, further evidence is required to clarify the phasing of multiple MET alterations, as well as to explain the mechanism of the preference for co-occurring MET fusions with METex14 in various tumor types.
We described a small molecular inhibitor, PLB-1001, with high potency and specificity for the MET kinase domain. Structural modeling indicates that the additional interaction sites of PLB-1001 with MET kinase domain increase its binding affinity and specificity compared with crizotinib. Treatment of cell line and xenograft with METex14 or ZM fusion with PLB-1001 resulted in MET signaling inhibition and reduced tumor volume. Despite several ongoing MET-targeting clinical trials in glioma (Pearson and Regad, 2017) , our study highlights a precision neurooncology approach by identifying patients with MET alterations. In our phase I clinical trial, PLB-1001 monotherapy demonstrated a safety profile for patients with ZM fusion and/or METex14. Moreover, 2/6 sGBM patients achieved PR, while SD was observed in 2/6 sGBM and 5/9 grade III glioma patients, indicating that PLB-1001 treatment is beneficial to not only sGBM but grade III glioma patients who harbored ZM and/or METex14. The lower response rate and short duration of response in patients may be contributed by the limited BBB penetration and intratumoral heterogeneity of gliomas. Nevertheless, our study provided an alternative therapeutic strategy for patients who have developed recurrent disease under TMZ-based standard therapy. Moreover, MET and ZM fusion are critical for chemoresistance in GBM (Huang et al., 2016; Zeng et al., 2017) , and knock down of MET sensitizes tumor cell lines in response to TMZ treatment . Given the lack of therapeutic options for recurrent tumor under TMZ treatment, our study has provided a promising therapeutic strategy of PLB-1001 mono-and combinatorial treatments with TMZ chemotherapy for patients with MET alterations.
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Sample inclusion criteria
By definition, secondary glioblastoma (sGBM) in this study refers to glioblastoma that developed from low grade glioma (LGG). Therefore, all the samples included in this study must have clear record of LGG diagnosis. Most of the samples were accompanied with a blood specimen as normal control.
Surgically removed sGBM samples were obtained from newly diagnosed patients treated by the AGGA Group. Tumor histology of all patients was confirmed independently by two neuropathologists based on the 2016 edition of WHO classification of central nervous system tumors. All the patients in the study received similar treatments.
Rodent models BALB/c nude mice
Female BALB/c nude mice (6-7 weeks old) were purchased from Charles River Laboratories. The mice were exposed to a 12-hour light/12-hour dark cycle, bred as specified-pathogen-free (SPF) and given food and water ad libitum. The mice were kept in the raising environment for a week before tumor cells transplantation. All procedures performed in this study were in accordance with instructions and permissions of the ethical committee of Beijing Tiantan Hospital. All mice were drug and test naive prior to initiating the experimental procedures performed and described in this paper.
Sprague-Dawley rats
Sprague-Dawley rats (12 males and 12 females) were purchased from Charles River Laboratories. The rats were 7-14 weeks old. The rats were bred in an SPF environment of 12-hour light/12-hour dark cycle and given food and water ad libitum. All experiment operations were in accordance with instructions and permissions of the ethical committee of Beijing Tiantan Hospital. All rats were drug and test naive. Cell culture models The human astrocytoma cell line U87 MG was obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences; the cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS (HyClone), 100 units/ml penicillin and 100 mg/ml streptomycin (Invitrogen) at 37 C in a humidified atmosphere of 5% CO 2 . Human astrocytes (ScienCell) were cultured according to the manufacturer's protocol in astrocyte medium (ScienCell) containing 5% FBS, astrocyte growth supplement and 1% penicillin/streptomycin. N33 cell line was derived from fresh glioma bulk of a female patient immediately after operation in Beijing Tiantan Hospital. The patient-derived cell line N33 has been authenticated after it could be passaged stably. The short tandem repeat analysis showed that N33 has no cross-contamination of other human cell lines, and no 100% match with any cell line in ATCC data bank or DSMZ data bank.
METHOD DETAILS
Sample processing and sequencing Genomic DNA from the tumor and the matched blood sample (where available) was extracted and confirmed for high integrity by 1% agarose gel electrophoresis. The DNA was subsequently fragmented, quality-controlled, and then pair-end libraries were prepared. For whole exome sequencing, Agilent SureSelect kit v5.4 was used for target capture. For targeted sequencing, a customized collection of 272 genes was captured using the Agilent SureSelectXT Custom kit. Sequencing was done on Illumina HiSeq 4000 platform using pair-end sequencing strategy. Samsung Medical Center (SMC) data was sequenced at SMC.
Total RNA from each tumor sample was extracted, and then depleted for tRNA and rRNA. After quality control and quantification, mRNA was reverse transcribed to cDNA, and then subjected to library preparation and sequencing.
Validation of METex14 by Sanger sequencing RNA extraction and reverse transcription of the glioma specimens were performed as mentioned above. PCR was performed to detect MET exon 14 skipping. The primers sequences were as follows: forward 5 0 -AATCTTTTATTAGTGGTGGGAGCACAAT-3 0 ; reverse 5 0 -GAATTAGGAAACTGATCTTTAATTTGC-3 0 . The reverse primer crosses exon 13 and exon 15 of MET. DNA polymerase (GoTaq, Promega) was used to amplify a 626-bp fragment with annealing temperature of 58 C. The product bands were extracted from agarose gel after electrophoresis and verified by Sanger sequencing.
Validation of PTPRZ1-MET fusion by Sanger sequencing RNA of the glioma specimens was isolated using the RNAprep pure Tissue Kit (Tiangen Biotech) followed by cDNA synthesis (RevertAid RT Kit, Thermo Fisher Scientific) according to the manufacturers' instructions. Primers flanking the fusion points of PTPRZ1-MET (ZM) (forward: 5 0 -CCGTCTGGAAATGCGAATCCTAAA-3 0 reverse: 5 0 -CAGGCCCAGTCTTGTACTCAGCAA-3 0 ) were used to clone the sequences crossing the fusion points with DNA polymerase (GoTaq, Promega). The forward and the reverse primers were designed based on the PTPRZ1 and MET segments that are common to all four fusion variants. Therefore, all four ZM fusion variants could be amplified using this pair of primers and amplifications of different sizes were produced (E1-E2: 337bp; E2-E2: 403bp; E3-E2: 583bp; E8-E2: 1207bp). The amplification product bands were extracted from agarose gel after electrophoresis and verified by Sanger sequencing. The sequencing reads were aligned to the known ZM fusion sequences to determine the presence and variant of ZM fusion in the given glioma specimen.
Histology and immunohistochemical staining Glioma specimens were fixed in 4% paraformaldehyde for 24 h and stored in 70% ethanol until paraffin embedding. Embedded tissue was processed to 5 mm sections and stained with hematoxylin and eosin (HE). Based on the HE staining, the histopathological type and the glioma grade were determined according to the 2007 World Health Organization classification system.
Immunohistochemical staining of the relevant proteins was performed on 5 mm paraffin sections from glioma tissue. The sections were then deparaffinized, rehydrated and treated in 10 mM citrate buffer (100 C, 10 min) for antigen repair. Subsequently, the sections were immersed in ethanol containing 3% hydrogen peroxidase for 10 min to block endogenous peroxidase activity. The sections were incubated overnight at 4 C with the primary antibodies at the indicated concentration dilutions, followed by 3 3 washing in phosphate-buffered saline and incubation with the secondary anti-rabbit or anti-mouse antibodies. The images were captured with Axio Imager 2 (Zeiss) after 3,3 0 -diaminobenzidine staining.
Immunoblotting
Tissue lysates or whole-cell lysates were prepared using RIPA buffer (Cell Signaling Technology). The protein concentration was detected by Coomassie Brilliant Blue using a micro plate spectrophotometer (Infinite M200 PRO, Tecan). Equal amounts of total protein (30 mg) from tissue or cell lysates were loaded on a 10% SDS/PAGE gel, transferred to a PVDF membrane (Merck Millipore), and detected using an ECL Western Blotting Detection System (Bio-Rad). Beta-Tubulin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the loading control. Goat anti-rabbit IgG-HRP or goat anti-mouse IgG-HRP were used as the secondary antibodies.
Generation of lentiviral vectors encoding ZM fusion and transduction of lentiviral vector
The coding sequence of the ZM fusion protein E2-E2 was cloned from glioma samples. The sequence was inserted into the lentiviral vector plasmid pCDH (System Biosciences). The pCDH plasmid carrying the fusion sequence was transduced into 293T cells with the lentiviral packaging plasmid mix (System Biosciences). The culture medium was collected once a day on two consecutive days and centrifuged with an ultracentrifuge at 25,000 rpm for 1.5 h. The precipitate was resuspended, aliquoted and stored at À80 C. This preparation was added to the U87 MG cell culture supplemented with 3 mg/ml polybrene (Sigma) in the medium. The medium was changed after 24 h. After 72 h, cells expressing the ZM fusion protein were selected during 3 days of treatment with puromycin. ZM fusion expression in the U87 MG cells was confirmed by RT-PCR.
Generation of adenoviral vectors encoding ZM fusions and transduction of adenoviral vectors
The human ZM E1-E2, ZM E2-E2 and METex14 coding sequences were amplified by PCR from cDNA derived from ZM-positive gliomas and cloned into a pShuttle-CMV vector. The sequences were then individually recombined into the pADxsi vector. Restriction enzyme digestion and sequencing were performed to confirm insertion of the right sequences. The recombinant plasmid was subsequently linearized by restriction enzyme digestion and transfected into HEK293A cells with Lipofectamine2000 (Thermo Fisher Scientific) for the generation of adenoviral vectors. The collected adenoviral vector was aliquoted and stored at À80 C before use. U87 MG cells, N33 or human astrocytes were separately treated in medium containing an appropriate titer of the adenoviral vector for 6h before medium change. ZM fusion and METex14 expression in each cell line was confirmed by RT-PCR.
Cell viability assay
The cells were seeded in 96-well plates at 800 cells per well in a total volume of 100 ml medium containing 10% FBS. During the following 6 days, cell viability was assessed everyday by MTS assay (CellTiter 96â AQueous One Solution Cell Proliferation Assay, Promega) according to the manufacturer's instructions.
Analysis of drug sensitivity in patient-derived cells
PDCs grown in serum-free medium were seeded in 384-well plates at a density of 500 cells per well in duplicate or triplicate for each drug treatment. PDCs were treated in a fourfold and seven-point serial dilution series from 4.88 nM to 20 mM. After 6 days of drug administration, cell viability was analyzed using ATP-monitoring system. Dose-response curve (DRC) fitting was performed using GraphPad Prism 5 and evaluated by measuring the Area Under the Curve (AUC) of the DRC. After normalization, best-fit lines were determined and AUC values were generated (Lee et al., 2018) .
Key information about PLB-1001 PLB-1001 (C20H15F3N8) is also known as CBI-3103, IDD-100 or Bozitinib. The chemical structure can be described as follows:
This compound was initially developed by Crown Bioscience. Beijing Pearl Biotechnology, LLC has an exclusive right over this compound in China (patent number: ZL201210322359).
Target inhibition assay
Selective inhibition of MET kinase by PLB-1001 was validated in a LANCE kinase assay performed by Cerep incorporation (France). The efficiency of PLB-1001 in inhibiting 100 kinases including MET was tested through detection of the level of ULight/CREBtidesubstrate phosphorylation after incubation with 2 mM of PLB-1001. Experimental conditions are indicated in Table S3 .
Drug permeability assay
Drug permeability assay was performed by in vitro ADME Laboratory of Pharmaron. Inc (Beijing, China). P-glycoprotein (P-gp) transporter, encoded by MDR1, is an efflux pump on cerebral endothelial cells which blocks drug delivery to the CNS. We employed the widely received blood-brain barrier model MDCK (Madin-Darby Canine Kidney)-MDR1 cell line (Cecchelli et al., 2007) expressing P-glycoprotein (P-gp) to compare the permeability and the efflux effects of PLB-1001 and four other MET targeted drugs (Crizotinib, Temozolomide, Cabozantinib and Foretinib). MDCK-MDR1 cells were seeded in 96-well transwell to form a confluent monolayer. After 4-7 days of culture, the monolayer integrity was checked with TEER (Transepithelial Electrical Resistance) measurement. The drugs (PLB-1001, Crizotinib, Temozolomide, Cabozantinib or Foretinib) were added at a final concentration of 1 mM to the upper chamber of transwell (chamber A). After incubation (37 C, 2h), concentrations of the infiltrated drugs in the lower chamber (chamber B) were detected with LC-MS/MS. Using the same methods, the concentrations of the drugs infiltrated from chamber B to chamber A were also detected. Apparent permeabilities were calculated with the formula: Efflux Rate = P appðB/AÞ P appðA/BÞ Caco-2 cell monolayers model was employed to evaluate the potential of PLB-1001 to be the substrate of Breast Cancer Resistance Protein (BCRP). Cells were seeded in 96-well transwell to form a confluent monolayer. The upper chamber to lower chamber (A/B) and lower chamber to upper chamber (B/A) transport of PLB-1001 in HBSS (25 mM HEPES, pH 7.4) was measured across Caco-2 cell monolayers in the absence and presence of BCRP inhibitor, Novobiocin (30 mM). Incubations were performed at approximately 37 C, for 120 min, with functionality of the test system being confirmed using 10 mM Rosuvastatin as a positive control BCRP substrate. Transport of 1 mM PLB-1001 and control compounds were determined by quantifying substrate concentration with LC-MS/MS in the incubation medium of donor (lower) compartment at the beginning of the incubation period, and both donor (lower) and receiver (upper) compartments at the end of the incubation period. The data was used to calculate the apparent permeability (P app ). P appðA/BÞ of PLB-1001 in the presence and absence of the BCRP inhibitor was compared, while P appðB/AÞ of BCRP substrate Rosuvastatin in the presence and absence of the BCRP inhibitor was used as positive control. Calculation formula of P app was as mentioned above.
Detection of PLB-1001 concentration in rat brain Sprague-Dawley rats (12 males and 12 females, Charles River Laboratories) aged 7-14 weeks underwent 16 h of fasting before intra gastric administration of 4.5 mg/kg of PLB-1001. After administration, the rats were given food and water ad libitum. At 0.25 h, 3 h, 12 h and 24 h after administration, whole blood of 6 rats including 3 male and 3 female was collected into centrifuge tube with heparin anticoagulant. Plasma was obtained after centrifugation and stored at À80 C. The rats were immediately sacrificed after blood collection. Brain tissue was collected and washed in normal saline, dried with filter paper and homogenized in purified water at a ratio of 1:5 (g/ml). Following vortexing with methanol and centrifugation, the supernatant was collected and analyzed using liquid chromatography using Prominence30A (Shimadzu) coupled with tandem mass spectrometry to determine the PLB-1001 concentration. PLB-1001 concentration in plasma was analyzed using liquid chromatography after thaw.
Subcutaneous xenografts and drug treatment U87 MG cells (1 3 10 6 ) transduced with a lentiviral vector expressing the ZM E2-E2 fusion or with a control vector were suspended in 100 mL PBS and injected subcutaneously into the flank of BALB/c nude mice (Charles River Laboratories). For experiments with MET inhibitors, mice carrying 100 mm 3 subcutaneous tumors were randomized to receive daily treatment with 50 mg/kg of Crizotinib or 10 mg/kg of PLB-1001 in 0.9% normal saline (injectable suspension) or an equal volume of normal saline by oral gavage. The tumor diameters were measured with a caliper, and the tumor volumes were estimated using the formula: 0.5 3 length 3 width 2 . The mice were sacrificed when the tumors in the control group had reached the maximal size allowed by the Institutional Animal Care and Use Committee.
Intracranial xenograft implantation and tissue preparation
Female BALB/c nude mice (7-8 weeks) were implanted in the brain with U87 MG cells expressing the ZM E2-E2 fusion or control vector. Briefly, the mice were anesthetized with 0.25 mL of a cocktail of 10 mg/ml ketamine and 1 mg/ml xylazine, and the cells were implanted using cranial guide screws as previously described (Liu et al., 2014) (coordinates relative to bregma: 2.0 mm posterior, 2.0 mm lateral, 3.0 mm ventral). A Hamilton syringe and a micro infusion syringe pump (1ml/min; Harvard Apparatus) were used to implant 3 3 10 5 cells into the brain. The intracranial tumors were detected by MRI. Upon detection of obviously poor general conditions, the mice were sacrificed by intracardiac perfusion of PBS and 4% paraformaldehyde. The brains were extracted and fixed in 10% formalin for 24 h, embedded in paraffin, and sectioned into 5-mm slices.
PLB-1001 treatment of intracranial xenograft mice model
Female BALB/c nude mice were implanted in the brain with U87 MG cells expressing the ZM E2-E2 fusion (5 3 10 5 cells/ mouse) to form orthotopic tumors. The intracranial tumors were detected by MRI. Mice carrying intracranial tumors with a volume of 80 mm 3 were randomized to receive 50 mg/kg of PLB-1001 in 0.9% normal saline (injectable suspension) or an equal volume of normal saline by oral gavage. Upon detection of obviously poor general conditions, the mice were sacrificed by intracardiac perfusion of PBS and 4% paraformaldehyde. The brains were extracted for histology and immunohistochemistry analyses.
Clinical trial of PLB-1001 treatment Study design and participants
We performed an open label, phase I, 3+3 dose-escalation study in Beijing (China; Table S5 ). The clinical trial was registered in National Clinical Trial (NCT02978261/ https://clinicaltrials.gov/ct2/show/NCT02978261) and approved by Medical Ethics Committee of Beijing Shijitan Hospital, Capital Medical University, Beijing, China. Eligible patients were over 18 years old, had pathologically confirmed recurrent high grade glioma, radiological progression after TMZ treatment with or without radiotherapy, a life expectancy of 3 months or more, RT-PCR followed by sanger sequencing validation of ZM expression, a Karnofsky Performance Scores (KPS) R 50, measurable disease per the Response Assessment of Neuro Oncology (RANO) criteria guidelines (Wen et al., 2017 ) (including patients with recurrent tumor surgically removed), stable or decreasing dose of corticosteroids within 5 days, and adequate bone marrow (platelet count R 75,000 per mL, absolute neutrophil count R 1,500 per mL, and haemoglobin concentration R 90 g/L), liver (total bilirubin concentrations, alanine aminotransferase and aspartate aminotransferase % 1.5 times the upper limit of normal (ULN)), and renal function (i.e., serum creatinine, urea nitrogen % 1.5 times ULN). Signed informed consent form was obtained from all patients. Exclusion criteria were previous or concurrent c-Met inhibitor or HGF-targeting therapy, presence of uncontrolled heart diseases, active peptic ulcer disease or gastritis, adverse events from prior anti-cancer therapy that have not resolved to Grade % 1 (except for alopecia), major surgical procedures in the preceding 4 weeks, pregnant or nursing women and involved in other clinical trials within 30 days.
Procedures PLB-1001 was provided by the sponsor (currently under development by Beijing Pearl Biotechnology, LLC) in the form of oral enteric capsule in 25 mg and 100 mg. We studied twice per day dosing of PLB-1001 with a modified Fibonacci dose-escalation design. The initially planned dose-escalation cohorts were 50 mg PLB-1001 twice per day, followed by 100 mg twice per day, followed by 200 mg twice per day, followed by 300 mg twice per day. If treatment was well tolerated (assessed weekly), patients continued treatment (at the planned level or frequency) until tumor progression reassessed by MRI or if patients were suspected to be unable to complete the trial. Patients were followed up weekly, MRI evaluation were performed monthly. All adverse events were monitored throughout the study period (until 28 days after participants' last PLB-1001 dose) and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE; version 4.03). Dose-limiting toxicity was defined as a grade 3 adverse event that was attributable to study treatment within 28 days after PLB-1001 treatment. Resumption of treatment for patients with a dose-limiting toxicity was permitted (when clinically appropriate) if the severity of the toxicity fell to grade I or lower and treatment was interrupted for no more than 2 weeks. Full clinical histories were taken at screening. MRI evaluation were done at baseline and every 4 weeks after PLB-1001 therapy. MRIs were independently reviewed by an expert radiologist on the basis of RANO criteria. Partial Response (PR) requires all of the following: 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 weeks; no new lesions; stable or reduced corticosteroid dose; and stable or improved clinically. Stable Disease (SD) defined by all of the following: does not qualify for complete response, partial response, or progression; and stable clinically. Progression Disease (PD) requires any of the following: 25% increase in sum of the products of perpendicular diameters of enhancing lesions; any new lesion; or clinical deterioration (Wen et al., 2010) . If treatment discontinuation was anticipated before expected time, patients were encouraged to undergo MRI earlier. Laboratory tests for hematology, chemistry and urinalysis were done within the 14 days before the first dose of PLB-1001. Physical examinations and assessments of PFS performance status were done every 4 weeks. If progressive disease (PD) was observed after assessment by RANO criteria, patients dropped out from the trial. Conversion from pharmacokinetics of PLB-1001 in xenografts transfected with ZM+ cell line to that of PLB-1001 in phase I clinical patients To relate the PLB-1001 free plasma concentration to the potential drug efficacy, we applied PLB-1001 in xenografts transfected with ZM+ cell line. For each dose, in vivo inhibition rate of tumor volume (IR TV ) was calculated. For example, when 60% tumor volume was reduced comparing with that in control group, we defined the dosage as effective dose 60 (ED60); when 90% tumor volume was reduced, we defined the dosage as effective dose 90 (ED90). The total and free plasma concentration in mouse was estimated following linear regression equation based on pharmacokinetics: Y = 1049.6X+1042, where Y represents total plasma concentration and X represents drug dosage in mouse.
Outcomes
The primary endpoints were to establish the maximum tolerated dose of PLB-1001 as measured by dose-limiting toxicity and to define the recommended phase II dosage (RP2D). Secondary endpoints were to characterize pharmacokinetic/pharmacodynamics (PK/PD) profile of PLB-1001, to assess the PLB-1001 concentration in CSF and to define the preliminary objective response according to the RANO criteria.
Statistical analysis
Analysis of tolerability and toxicity was based on all patients in each dosing cohort who received at least one cycle (28 days) of one dose of the study drug. The maximum tolerated dose was based on the dose-limiting toxicities noted during PLB-1001 treatment. We used descriptive statistics to summarize AE data. We summarized response analysis that was done in patients who underwent a baseline assessment and at least one scheduled post-baseline tumor assessment by MRI. We collected CSF concentration of PLB-1001 in all patients for comparison analysis with parameters of plasma pharmacokinetics. All statistical tests were two-sided and assumed a two-sided significance level of 0.05.
QUANTIFICATION AND STATISTICAL ANALYSIS
Mapping and mutation calling Valid DNA sequencing data were mapped to the reference human genome (UCSC hg19) using Burrows-Wheeler Aligner (bwa mem) with default parameters. Then, SAMtools and Picard (Broad Institute) were used to sort the reads by coordinates and mark duplicates (mark duplication was not done for deep sequencing). Statistics such as sequencing depth and coverage were calculated based on the resultant BAM files.
SAVI2 was used to identify somatic mutations (including single nucleotide variations and short insertion/deletions) as previously described. In this pipeline, SAMtools mpileup and bcftools were used to perform variant calling, then the preliminary variant list was filtered to remove positions with no sufficient sequencing depth, positions with only low-quality reads, and positions that are biased toward either strand. Somatic mutations were identified and evaluated by an Empirical Bayesian method. In particular, mutations with the mutation allele frequency in tumors significantly higher than that in normal control were selected . The reported mutations were further selected based on known driver genes of LGG and glioblastoma .
Copy number alteration analysis
For WES and target sequencing data, Excavator2 was used to estimate CNA (copy number alteration) status of the known driver genes of glioma, including CIC, FUBP1, CDKN2A, CDK4, MDM2, MET, EGFR, PTEN, PDGFRA and TP53. The window size was selected as 10,000, and all other parameters were as default.
XCAVATOR, which uses the same algorithm as EXCAVATOR2, was used to analyze CNA in whole genome sequencing data. Window size was set to be 10000, and other default parameters were used.
Hypermutation detection
Hypermutated samples were detected using an in-house software based on a scaled mutation load (ML) per sample and a hypermutation score (HM) . For the samples without matched normal sample sequenced, we filtered out the SNPs recorded in the dbSNP database (Sherry et al., 2001) . For identification of mutations using RNA-sequencing data, we did not consider the mutations located in splicing sites. After filtering of significant mutations, we considered the number of significant mutations as the mutation load for targeted-sequencing and RNA-sequencing data, and the mutation load for whole-exome sequencing data is the number of significant mutations divided by 10. The hypermutation score (HM Score) was defined based on our previous study and the TMZ-treatment-related signature (Signature 11) (Alexandrov et al., 2013) as
where the function f C-> T (x) is the number of mutations from cytosine C to thymine T followed by a nucleotide x along the 3-prime direction in the reference genome, and the function sign(y) = 1 if y > = 0, and À1 otherwise. The letter N denotes any bases A, T, G or C. The three terms in the HM score are designed to capture the three features of hypermutated samples due to TMZ treatment:
(1) the dominant mutation type is C-> T, (2) those C-> T mutations are primarily followed by a nucleotide C, and (3) T is the second most succeeding nucleotide of the C-> T mutated sites. The in-house software will be available under request.
Detection of gene fusions from RNA sequencing Chimerascan (Iyer et al., 2011) was used to produce a gene fusion candidates from RNA sequencing data and then further annotated with Pegasus (Abate et al., 2014) . The fusions were selected by: (i) Pegasus score > 0.5; (ii) either more than 400 spanning reads or at least 2 split reads supporting fusion; and (iii) the two fusion partners being separated from each other by at least 50 kb.
Detection of METex14 from RNA sequencing
We detected MET exon 14 skipping based on spanning reads over the junction of exon 13 and exon 15. Briefly, RNA sequencing reads were aligned to the reference genome (hg19) using STAR, and then the reads containing a jump of 3226 bp from chr7:116411700 were counted. The spanning reads were manually checked in Integrative Genomic Viewer to remove false positives such as PCR artifacts and potential mapping errors. Sashimi plot was used to visualize the skipping reads.
Definition of sGBM Specificity
To measure the specificity of an alteration in sGBM compared with LGG and pGBM, the fold change was calculated using the following formula:
sGBM specificity = s 3 ðP + LÞ S 3 ðp + lÞ where s; p; l represent the number of altered sGBM, pGBM, LGG patients respectively, while S; P; L stand for that of total sGBM, pGBM and LGG cases.
Gene expression analysis and GSEA
The human reference genome hg19, and genome annotation file were downloaded from UCSC genome browser. The clean RNA sequencing reads were mapped to the reference genome using STAR. Gene expression, in FPKM, was calculated by Cufflinks. Differentially expressed genes were selected based on fold change and adjusted P value which was calculated by DESeq2. GSEA was used for gene set enrichment analysis. Normalized enrichment scores (NES) were calculated for gene sets which were downloaded from MSigDB database version 6.1 (http://software.broadinstitute.org/gsea/msigdb).
Immune cell gene signatures
Gene expression level, represented as FPKM, was processed by Cibersort (Newman et al., 2015) under absolute mode. The resultant absolute immune fraction scores of 22 immune cell types between different groups were compared using Wilcoxon rank-sum test.
DATA AND SOFTWARE AVAILABILITY
The accession numbers for sequencing data reported in this paper are EGAS00001003188, EGAS00001000579, EGAS00001001033, EGAS00001001044, EGAS00001001041, EGAS00001001800; SRA: SRP074425; GEO: GSE48865.
ADDITIONAL RESOURCES
This study involves an open label, phase I, 3+3 dose-escalation study in Beijing (China; Figure S5 . Clinical Records of Grade III Glioma Patients Enrolled in PLB-1001 Trial, Related to Figure 6 (A) Diagram of the glioma progression and treatment in patient P01003. Patient P01003 was a 41-year-old female, diagnosed with anaplastic astrocytoma (AA) after 9 years since the initial astrocytoma (A) was resected and treated with TMZ following radiotherapy. ZM fusion was detected in the AA sample. The patient was later subscribed with TMZ concurrent with radiotherapy followed by 8 cycles of TMZ and PLB-1001 treatment (50 mg bid), subsequently. MRI evaluation after 4 week of PLB-1001 treatment demonstrated increased tumor volume. The patient deceased with a 518-day PPS. (B) Diagram of the glioma progression and treatment in patient P01004. Patient P01004 was a 38-year-old male, diagnosed with AA after 3 years since the initial anaplastic oligodendroglioma (AO) was resected and treated with TMZ concurrent with radiotherapy followed by 4 cycles of TMZ subsequently. ZM fusion was detected in the AA sample, and the patient was later subscribed with PLB-1001 treatment (50 mg bid). MRI evaluation after 12 weeks of PLB-1001 treatment demonstrated stable tumor volume. The patient is still alive with a 565-day PPS.
Supplemental Figures
(legend continued on next page) (C) Diagram of the glioma progression and treatment in patient P01005. Patient P01005 was a 54-year-old male with AA. Since the initial low grade A was treated with radiotherapy, the tumor recurred locally and progressed into AA. ZM fusion was detected in the AA sample, and the patient was later subscribed with 2 cycles of TMZ treatment followed by 3 cycles of PLB-1001 treatment (100 mg bid). MRI evaluation after 12 weeks of PLB-1001 treatment demonstrated stable tumor volume accompanied by symptom relief. The patient is still alive with a 492-day PPS. (D) Diagram of the glioma progression and treatment in patient P01007. Patient P01007 was a 45-year-old male, diagnosed with AA after 4 years since the initial anaplastic oligodendroastrocytoma (AOA) was resected and treated with TMZ following radiotherapy. ZM fusion was detected in the AA sample, and the patient was later subscribed with PLB-1001 treatment (100 mg bid). MRI evaluation after 4 week of PLB-1001 treatment demonstrated increased tumor volume. The patient deceased with a 276-day PPS. (E) Diagram of the glioma progression and treatment in patient P01010. Patient P01010 was a 32-year-old male, diagnosed with AA after 5 years since the initial A was resected and treated with radiotherapy. ZM fusion was detected in the AA sample. The patient was later subscribed with TMZ treatment followed by PLB-1001 treatment (200 mg bid), subsequently. MRI evaluation after 12 weeks of PLB-1001 treatment demonstrated a new recurrent lesion. The patient is still alive with a 445-day PPS. (F) Diagram of the glioma progression and treatment in patient P01012. Patient P01012 was a 54-year-old female, diagnosed with AA after 6 years since the initial A was resected and treated with radiotherapy. ZM fusion was detected in the AA sample. The patient was later subscribed with 8 cycles of TMZ treatment followed by PLB-1001 treatment (300 mg bid). MRI evaluation after 12 weeks of PLB-1001 treatment demonstrated stable tumor volume. The patient is still alive with a 524-day PPS. (legend continued on next page) (D) The mean free fraction for PLB-1001 in human blood was 1.2%. The average free plasma concentration was then calculated based on the total plasma concentration of patients in phase I clinical trial. The 60% effective dose (ED60) and 90% effective dose (ED90) were inferred from preclinical mouse model. Data was shown in Table S6 . (E) The tumor in Patient P01011 under PLB-1001 treatment was monitored by MRI evaluation every 4 weeks. The tumor was located on right temporal and insular lobe. We defined 1st MRI evaluation after PLB-1001 treatment as the baseline evaluation. MRI evaluation after 16 weeks of PLB-1001 treatment demonstrated decreased enhancement and tumor shrinkage accompanied by symptom relief. No radiological progression was detected until 20 weeks after PLB-1001. The location of tumor is marked by arrowhead.
